Skip to Main Content

Paper Details

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Cancer Chemotherapy and Pharmacology
13
2021
AR, AR-42, DLTs, NF2, NF2-related meningioma, Sertoli cell carcinoma, advanced solid malignancies, advanced solid tumors, breast cancer, carcinoma of unknown, cytopenias, fatigue, hematologic malignancies, histone deacetylase, meningioma, nausea, neurofibromatosis type 2-associated meningiomas, neurofibromatosis type 2-associated tumors, non-, patients, psychosis, schwannomas, small cell lung cancer, solid tumors, thrombocytopenia, uveal melanoma
Author NameAffiliation
Craig C HofmeisterWinship Cancer Institute of Emory University
  • 1 - 1

Datasets

Release 1.2